Last reviewed 2026-04-20 · How we verify

AMG 592

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Injection site erythema
• Headache
• Rash
• Urticaria
• Injection site pruritus
• Injection site rash
• Palpitations
• Fatigue
• Injection site discolouration
• Injection site pain
• Pain
• Pyrexia

Key clinical trials

• Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE2)
• Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis (PHASE2)
• Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus (PHASE2)
• Study of Efavaleukin Alfa in Healthy Chinese, Japanese, and Caucasian Participants (PHASE1)
• Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease (PHASE1, PHASE2)
• A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants (PHASE1)
• A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants (PHASE1)
• Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• AMG 592 CI brief — competitive landscape report
• AMG 592 updates RSS · CI watch RSS
• Amgen portfolio CI